Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Receives US Patents Covering VeriStrat Test

Premium

Biodesix this week announced it has been issued four US patents covering intellectual property underlying its protein biomarker-based companion diagnostic VeriStrat, providing coverage for the product across multiple tumor types.

Specifically, the patents cover the selection of non-small cell lung cancer patients for treatment with antibodies targeting the epidermal growth-factor receptor pathway; and the selection of colorectal cancer patients and head and neck cancer patients for treatment with drugs targeting the epidermal growth-factor receptor pathway. The company also received a patent covering its laboratory operations.

Biodesix launched VeriStrat commercially in May 2009, offering it out of its CLIA-accredited laboratory. In March, the company received CLIA certification in New York, making the test available in all 50 states (PM 03/04/2011).

During the JP Morgan Healthcare Conference in January, Biodesix's vice president of business development and strategic marketing, Paul Beresford, told ProteoMonitor sister publication GenomeWeb Daily News that the company was looking to forge pharmaceutical partnerships to increase adoption of VeriStrat and was in the process of signing approximately 20 deals around the test (GWDN 01/21/2011).

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.